ACE2 and neoplasm: Treatment of ccRCC xenografts with VEGFR-TKIs reduces ACE2 expression, while the combination of VEGFR-TKIs and Ang-(1–7) produces an additive inhibitory effect on tumor growth and improves survival outcomes.